{"symbol":"REGN","fiscalQuarter":"Q4-2021","reportDate":"2022-02-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2021","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.37%","keyNumbers":[{"metric":"EPS","actual":"$23.72","expected":"N/A","surprise":"+28.26%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our performance this quarter.","Our focus remains on innovation and meeting patient needs."],"summary":"Management expressed satisfaction with the earnings results, highlighting their commitment to innovation. They emphasized the importance of continuing to meet patient needs in the coming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported strong earnings with an EPS beat, which contributed to a slight increase in stock price. The positive surprise in EPS indicates strong operational performance, although no revenue figures were disclosed. The stock reaction suggests that investors are encouraged by the earnings results, even without specific guidance for the future.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2021 earnings: EPS beat by 28.26%. Stock up 0.37%. Full breakdown."}}